RAPT Therapeutics Inc
RAPT10.665USD
+0.175+1.67%
Market hours （ET）Quotes delayed by 15 min
175.98MMarket Cap
LossP/E TTM
More Details of RAPT Therapeutics Inc Company
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Company Info
Ticker SymbolRAPT
Company nameRAPT Therapeutics Inc
IPO dateOct 31, 2019
CEODr. Brian Wong, M.D., Ph.D.
Number of employees68
Security typeOrdinary Share
Fiscal year-endOct 31
Address561 Eccles Ave
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94080
Phone16504899000
Websitehttps://rapt.com/
Ticker SymbolRAPT
IPO dateOct 31, 2019
CEODr. Brian Wong, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
Shareholder Types
Shareholders
Proportion
Private Equity
22.72%
Hedge Fund
21.17%
Investment Advisor
19.56%
Venture Capital
17.98%
Investment Advisor/Hedge Fund
16.93%
Research Firm
0.60%
Individual Investor
0.44%
Bank and Trust
0.09%
Family Office
0.02%
Other
0.50%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
295
16.46M
99.56%
-1.03M
2025Q1
309
29.14M
109.47%
+11.54M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
2023Q2
295
35.63M
103.77%
-4.21M
2023Q1
301
34.71M
101.29%
-3.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Medicxi Ventures (UK) LLP
2.79M
16.9%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
1.64M
9.93%
--
--
Mar 31, 2025
TCG Crossover Management, LLC
1.64M
9.9%
-5.63K
-0.34%
Mar 31, 2025
Foresite Capital Management, LLC
1.56M
9.45%
--
--
Mar 31, 2025
RTW Investments L.P.
1.47M
8.89%
--
--
Mar 31, 2025
BVF Partners L.P.
1.15M
6.98%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
6.26%
+668.30K
+182.32%
Mar 31, 2025
Redmile Group, LLC
809.41K
4.89%
--
--
Mar 31, 2025
Deep Track Capital LP
751.42K
4.54%
--
--
Mar 31, 2025
Adar1 Capital Management LLC
746.35K
4.51%
+599.56K
+408.45%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
Nuveen ESG Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Humankind US Stock ETF
0%
Invesco Dorsey Wright Healthcare Momentum ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
SPDR S&P Biotech ETF
0%
View more
ProShares UltraPro Russell2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Nuveen ESG Small-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Humankind US Stock ETF
Proportion0%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
SPDR S&P Biotech ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
